Internal Medicine H, Sourasky Medical Centre, Tel Aviv & Sackler School of Medicine, Tel Aviv University, Israel.
Institute of Endocrinology Metabolism and Hypertension, Sourasky Medical Centre, Tel Aviv & Sackler School of Medicine, Tel Aviv University, Israel.
Clin Exp Rheumatol. 2021 May-Jun;39 Suppl 130(3):27-32. doi: 10.55563/clinexprheumatol/pq0qp6. Epub 2021 Jan 13.
As members of a gender minority, transgender individuals face many challenges. Many experience distress, depression, anxiety and suicidal ideation related to gender non-conformity and transphobia. Stress and trauma may contribute to the development of fibromyalgia (FM) syndrome, characterised by widespread pain and fatigue. The prevalence of FM among transgenders is not known.
Transgender participants were recruited at a specialised clinic. Questionnaires included the Widespread Pain Index (WPI), the Symptom Severity Score (SSS) and the SF-36. Data concerning hormonal treatment protocols was retrieved from charts. The current prevalence of FM was determined, as well as the prevalence before and after testosterone treatment among TM. Pearson correlations were calculated between all measures.
115 participants were recruited, 62.6% transgender men (TM), 37.4% transgender women (TW). 17 individuals (14.8%) fulfilled the 2011 modified ACR FM criteria, for a rate of 19.4% among TM and 6.98% among TW. Among TM, FM was associated with younger age, smoking and SF-36 sub-scales related to physical functioning, role limitation due to physical pain, fatigue, pain and general health. Among TW, FM was associated with social status, employment, depression, existing medical treatment and substance abuse, as well as SF-36 subscales related to role limitations affected due to pain.
Fibromyalgia symptoms are highly prevalent among Israeli transgender individuals and may be related to psychological distress and gender dysphoria. Healthcare professionals treating transgenders should remain vigilant for the occurrence of chronic pain, fatigue and other FM-related symptoms and be prepared to treat and/or refer such patients accordingly.
作为性别少数群体的一员,跨性别者面临许多挑战。许多人由于性别不一致和跨性别恐惧症而感到痛苦、抑郁、焦虑和自杀意念。压力和创伤可能导致纤维肌痛(FM)综合征的发展,其特征是广泛的疼痛和疲劳。跨性别者中 FM 的患病率尚不清楚。
在专门的诊所招募跨性别者参与者。问卷包括广泛疼痛指数(WPI)、症状严重程度评分(SSS)和 SF-36。从图表中检索有关激素治疗方案的数据。确定当前 FM 的患病率,以及 TM 接受睾丸激素治疗前后的患病率。计算所有测量值之间的 Pearson 相关性。
共招募 115 名参与者,62.6%为跨性别男性(TM),37.4%为跨性别女性(TW)。17 名个体(14.8%)符合 2011 年修订的 ACR FM 标准,TM 中的患病率为 19.4%,TW 中的患病率为 6.98%。在 TM 中,FM 与年龄较小、吸烟以及与身体功能相关的 SF-36 子量表、因身体疼痛而导致的角色限制、疲劳、疼痛和一般健康相关。在 TW 中,FM 与社会地位、就业、抑郁、现有治疗和药物滥用以及与疼痛相关的角色限制障碍的 SF-36 子量表相关。
纤维肌痛症状在以色列跨性别者中高度普遍,可能与心理困扰和性别焦虑有关。治疗跨性别者的医疗保健专业人员应保持警惕,注意慢性疼痛、疲劳和其他 FM 相关症状的发生,并准备好相应地治疗和/或转介此类患者。